Compare BWA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWA | JAZZ |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 10.4B |
| IPO Year | 1995 | 2007 |
| Metric | BWA | JAZZ |
|---|---|---|
| Price | $55.70 | $201.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | $57.88 | ★ $217.00 |
| AVG Volume (30 Days) | ★ 1.7M | 844.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $14,316,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $1.54 | $6.22 |
| Revenue Next Year | $3.54 | $7.68 |
| P/E Ratio | $42.73 | ★ N/A |
| Revenue Growth | ★ 1.63 | N/A |
| 52 Week Low | $27.37 | $103.65 |
| 52 Week High | $70.08 | $207.48 |
| Indicator | BWA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 61.89 |
| Support Level | $51.43 | $159.78 |
| Resistance Level | $56.23 | N/A |
| Average True Range (ATR) | 1.26 | 4.97 |
| MACD | 0.22 | 0.35 |
| Stochastic Oscillator | 80.54 | 70.28 |
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.